SCHEMBL17015237

SCHEMBL17015237

c1ccc(-c2ccc3c(c2)c2ccccc2n3-c2cccc(-n3c4ccccc4c4ccc5c(ccn5-c5ccccc5)c43)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TSPO P30536 3/20 0.35
MAOB P27338 1/20 0.33
WNK1 Q9H4A3 1/20 0.33
DNM1 Q05193 1/20 0.33
HTR7 P34969 1/20 0.33
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
HDAC4 P56524 1/20 0.31
METTL3 Q86U44 1/20 0.31
METTL14 Q9HCE5 1/20 0.31
KMT2A Q03164 2/20 0.30
IL1R1 P14778 1/20 0.30
PTGER4 P35408 1/20 0.30
KDR P35968 1/20 0.30
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015238 1.00 KDM4E (0.40) KDM4EATML3MBTL1TSPOMAOB
SCHEMBL17015708 0.99 KDM4E (0.39) KDM4EATML3MBTL1TSPOMAOB
SCHEMBL17015710 0.99 KDM4E (0.39) KDM4EATML3MBTL1TSPOMAOB
SCHEMBL17016192 0.96 L3MBTL1 (0.42) KDM4EATML3MBTL1TSPOMAOB
SCHEMBL17016190 0.96 L3MBTL1 (0.42) KDM4EATML3MBTL1TSPOMAOB
SCHEMBL17015242 0.95 KDM4E (0.40) KDM4EATML3MBTL1TSPOMAOB
SCHEMBL17015705 0.95 L3MBTL1 (0.41) KDM4EATML3MBTL1MAOBWNK1
SCHEMBL17015788 0.94 KDM4E (0.37) KDM4EATML3MBTL1TSPOMAOB
SCHEMBL17015792 0.94 KDM4E (0.37) KDM4EATML3MBTL1TSPOMAOB
SCHEMBL17015239 0.94 KDM4E (0.39) KDM4EATML3MBTL1TSPOMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.